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ttp://dx.doi.org/10.1016/j.ajpath.2014.08.030Inﬂuenza A virus infections in humans generally cause self-limited infections, but can result in severe
disease, secondary bacterial pneumonias, and death. Inﬂuenza viruses can replicate in epithelial cells
throughout the respiratory tree and can cause tracheitis, bronchitis, bronchiolitis, diffuse alveolar damage
with pulmonary edema and hemorrhage, and interstitial and airspace inﬂammation. The mechanisms by
which inﬂuenza infections result in enhanced disease, including development of pneumonia and acute
respiratory distress, are multifactorial, involving host, viral, and bacterial factors. Host factors that
enhance risk of severe inﬂuenza disease include underlying comorbidities, such as cardiac and respiratory
disease, immunosuppression, and pregnancy. Viral parameters enhancing disease risk include polymerase
mutations associated with host switch and adaptation, viral proteins that modulate immune and antiviral
responses, and virulence factors that increase disease severity, which can be especially prominent in
pandemic viruses and some zoonotic inﬂuenza viruses causing human infections. Inﬂuenza viral infections
result in damage to the respiratory epithelium that facilitates secondary infection with common bacterial
pneumopathogens and can lead to secondary bacterial pneumonias that greatly contribute to respiratory
distress, enhanced morbidity, and death. Understanding the molecular mechanisms by which inﬂuenza
and secondary bacterial infections, coupled with the role of host risk factors, contribute to enhanced
morbidity and mortality is essential to develop better therapeutic strategies to treat severe inﬂuenza.
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This article is part of a review series on infectious disease.Inﬂuenza viruses are important pathogens from a public
health perspective, because they are common causes of
human respiratory illness. Signiﬁcantly, inﬂuenza infections
are associated with high morbidity and mortality, especially
in elderly persons, infants, and those with chronic diseases.1
Human inﬂuenza virus infections are associated with
endemically circulating strains causing annual or seasonal
epidemic outbreaks (usually in the winter months) and oc-
casional and unpredictably emerging pandemic strains, as
well as zoonotic infections from avian and mammalian an-
imal hosts.
Epidemic inﬂuenza infection results in up to 49,000
deaths and 200,000 hospitalizations each year in the United
States alone.2 However, pandemic strains of inﬂuenza can
cause even higher mortality. For example, the 1918 Spanish
inﬂuenza pandemic resulted in approximately 675,000
deaths in the United States in a population approximatelyogy.one-third the size of the current population and approxi-
mately 50 million deaths globally.3,4 Since 1997, there has
been heightened concern that avian inﬂuenza viruses asso-
ciated with zoonotic outbreaks, such as H5N1 and H7N9,
could adapt to achieve efﬁcient transmissibility in humans
and cause a pandemic.5
Inﬂuenza virus infections are generally acute, self-limited
infections.6 Clinically, inﬂuenza manifests as an acute res-
piratory disease characterized by the sudden onset of high
fever, coryza, cough, headache, prostration, malaise, and
inﬂammation of the upper respiratory tree and trachea.
Acute symptoms and fever often persist for 7 to 10 days,
Figure 1 Diagram showing interrelationships between viral genes, host
factors, and secondary bacterial infections associated with development of
severe pathology and disease. ARDS, acute respiratory distress syndrome; HA,
hemagglutinin; PAX, polymerase acidic frameshift protein; PB1, polymerase
basic protein 1 frame 2 protein; SNP, single-nucleotide polymorphism.
Inﬂuenza Pathogenesisand in most cases, the infection is self-limited. Generally,
pneumonic involvement is not clinically prominent,
although weakness and fatigue may linger for weeks. People
of all ages are afﬂicted, but the prevalence is greatest in
school-aged children; disease severity is greatest in infants,
elderly persons, and those with underlying illnesses. Inﬂu-
enza A viral replication peaks approximately 48 hours after
infection of the nasopharynx and declines thereafter, with
little virus shed after approximately 6 days. The virus rep-
licates in both the upper and lower respiratory tract. The
diagnosis of inﬂuenza can be established by viral culture,
demonstration of viral antigens, demonstration of viral ge-
netic material (in clinical specimens), or changes in speciﬁc
antibody titers in serum or respiratory secretions.7
Inﬂuenza is the leading cause of respiratory viral disease
in all hospitalized patients >16 years.8 People with under-
lying comorbidities, including chronic pulmonary or cardiac
disease, immunosuppression, or diabetes mellitus, are at
high risk of developing severe complications from inﬂuenza
A viruses (IAVs). These may include hemorrhagic bron-
chitis, laryngotracheitis in young children, pneumonia (pri-
mary viral or secondary bacterial), and death.6,9 Obesity has
recently been identiﬁed as an independent risk factor, and
pregnancy has long been associated with increased risk.10,11
Complications of inﬂuenza, including hemorrhagic bron-
chitis, diffuse alveolar damage, and pneumonia, can develop
within hours. Fulminant fatal inﬂuenza viral pneumonia oc-
casionally occurs, but most pneumonias are caused by sec-
ondary bacterial infections.12,13 Development of pneumonia,
dyspnea, cyanosis, hemoptysis, pulmonary edema leading to
acute respiratory distress syndrome, and deathmay proceed in
as little as 48 hours after the onset of symptoms. Progression
to severe disease, including development of acute respiratory
distress, pneumonia, and death, is likely a multifactorial
process involving viral, host, and bacterial factors (Figure 1).
In this review, we will examine each of these underlying
factors to discuss their contribution to inﬂuenza pathogenesis.
Inﬂuenza A Virus Ecobiology
Overview
Inﬂuenza viruses (of the family Orthomyxoviridae) are
enveloped, negative-sense, single-stranded RNAviruseswith
segmented genomes. There are ﬁve genera, including Inﬂu-
enzavirus A, Inﬂuenzavirus B, Inﬂuenzavirus C, Thogotovi-
rus, and Isavirus (infectious salmon anemia virus).1,14,15
The Inﬂuenzavirus genera differ in host range and path-
ogenicity and diverged evolutionarily at least several thou-
sand years ago.16 Inﬂuenza A and B viruses have a similar
structure, whereas inﬂuenza C is more divergent. Inﬂuenza A
and B type viruses contain eight discrete single-stranded
RNA gene segments, each encoding at least one protein.
Inﬂuenza B and C viruses are predominantly human-adapted
viruses, whereas IAVs naturally infect hundreds of warm-
blooded animal hosts, including both avian and mammalianThe American Journal of Pathology - ajp.amjpathol.orgspecies. Wild aquatic birds are the major reservoir of IAV,
where it causes predominantly asymptomatic gastrointestinal
tract infections.17 Mixed IAV infections and gene segment
reassortment are common in wild aquatic birds. These data
suggest that IAVs in wild birds form transient genome con-
stellations without the strong selective pressure to be main-
tained as linked genomes, leading to the continual emergence
of novel genotypes.18 This genetic and antigenic diversity of
IAVs thus poses a signiﬁcant risk of zoonotic infection, host
switch events, and the generation of pandemic IAV strains.
IAVs encode at least 13 proteins via alternative open reading
frames, splicing, or ribosomal frame shifting.19
Viral Surface and Structural Proteins
IAVs express three surface proteins: hemagglutinin (HA),
neuraminidase (NA), and matrix 2. IAVs are classiﬁed, or
subtyped, by antigenic or genetic characterization of the HA
and NA glycoproteins. Eighteen different HA and 11
different NA subtypes are known,18,20 with 16 of the HAs
and 9 of the NAs consistently found in avian hosts in
various combinations (eg, H1N1 or H3N2).18,20 HA is a
glycoprotein that functions both as the viral receptor-
binding protein and as the fusion protein. HA binds to
sialic acid (N-acetyl neuraminic acid) bound to underlying
sugars on the tips of host cell glycoproteins. IAVs have HAs
with varying speciﬁcities for the disaccharide consisting of
sialic acids (SAs) and the penultimate sugar (galactose or
N-acetylgalactosamine) with different glycosidic bonds.
IAVs adapted to birds typically have HA receptor binding
speciﬁcity for a2,3 SA, whereas HAs from IAVs adapted to
humans have higher speciﬁcity for a2,6 SA.1,141529
Kash and TaubenbergerAfter receptor binding, the virus is internalized. The
endosomal compartment’s acidic pH leads to an HA
conformational change, facilitating fusion of the viral and
endosomal membranes, release of viral ribonucleoproteins
(RNPs) into the cytoplasm, and their subsequent transport to
the nucleus. Viral HA is a homotrimer, and each monomer
undergoes proteolytic cleavage to generate HA1 and HA2
polypeptide chains before activation. IAV does not encode a
protease and requires exogenous serine proteases (trypsin-
like enzymes) for activation that recognize a conserved Q/E-
X-R motif found at the HA cleavage site.21 In humans and
other mammals, Clara tryptase, produced by cells of the
bronchiolar epithelium, likely serves this role. IAVs of H5
and H7 subtypes can acquire insertional mutations at the HA
cleavage site, which change their protease recognition site to
a furin-like recognition sequence R-X-R/K-R. This poly-
basic cleavage site broadens protease speciﬁcity, allowing
for intracellular cleavage activation, and systemic replica-
tion of such viruses in poultry, resulting in the emergence of
highly pathogenic avian inﬂuenza.
NA is a glycoprotein with neuraminidase (sialidase) enzy-
matic activity required for cleavage of these host cell SAs,
allowing newly produced virions to be released and to cleave
SAs from viral glycoproteins to prevent aggregation of nascent
viral particles. The surface glycoproteins HA and NA are the
major antigenic targets of the humoral immune response to
IAV, and NA is the target of the antiviral drugs oseltamivir and
zanamivir. The matrix 1 protein is the most abundant structural
protein. Localized beneath the viral membrane, it interacts with
the cytoplasmic domains of the surface glycoproteins HA and
NA and also with the viral RNP complexes. The small protein
matrix 2 is a proton channel necessary for viral replication and
is the target of the adamantane class of antiviral drugs.22 Matrix
2 functions as a low pH gated ion channel that lowers the pH of
the virion after internalization and leads to membrane fusion
with the lysogenic vacuole. The viral RNPs are released into the
cytoplasm and are then translocated to the nucleus to initiate
viral RNA synthesis.
Viral RNA Polymerase
IAVs are segmented, negative-stranded viruses, and viral
RNPs consist of each RNAgene segment, encapsidated by the
single-stranded RNA binding protein nucleoprotein (NP) and
associated with three viral polymerase proteins that comprise
the RNA-dependent RNA polymerase-polymerase basic pro-
tein 2 (PB2), polymerase basic protein 1 (PB1), and poly-
merase acidic protein (PA). The polymerase proteins form a
heterotrimer bound to short hairpin structures formed by the
complementary terminal 50 and 30 untranslated regions of each
RNA segment. PB1 is the RNA-dependent RNA polymerase,
and PB2 functions inmRNAsynthesis by binding hostmRNA
caps. Although PA is necessary for a functional polymerase
complex, including endonucleolytic cleavage of host pre-
mRNAs, its biological roles remain less well understood. NP
plays important roles in transcription, and in the trafﬁcking of1530RNPs between the cytoplasm and nucleus. IAV is dependent
on the RNA processing machinery of the host cell, and tran-
scription and replication occur in the host nucleus.
Non-Structural Proteins
Several non-structural proteins play important roles in the
viral replicative cycle. The non-structural protein 1 has a
variety of functions, including double-stranded RNA bind-
ing and antagonism of host cell type I interferon re-
sponses.14 The NS2 (or NEP) protein enables nuclear export
of viral RNP complexes. PB1-F2 targets the mitochondrial
inner membrane and may play a role in apoptosis during
IAV infection.23 PAX is a newly discovered protein that
functions to repress cellular gene expression and modulates
IAV pathogenicity by an unknown mechanism.24
Polymerase Inﬁdelity and Viral Evolution
The viral RNA-dependent RNA polymerase lacks proof-
reading, and IAVs are thus evolutionarily dynamic viruseswith
high mutation rates that range from approximately 1 103 to
8  103 substitutions per site per year.25 Mutations that alter
amino acids in the antigenic portions of the surface glycopro-
teins HA and NA may allow IAVs to evade preexisting im-
munity. These mutations are especially important in human
seasonal IAV strains, which are subjected to strong population
immunological pressures. Anti-HA antibodies can prevent re-
ceptor binding, can neutralize infection, and are effective at
preventing reinfection with the same strain. This selective
mutation in the antigenic domains of HA and NA has been
termed antigenic drift26 and is the basis for the need to yearly
update the annual inﬂuenza vaccine formulation.1
The high mutation rate can also result in the rapid estab-
lishment of antiviral drug-resistant populations, including
resistance to NA inhibitors and adamantanes. Clinical studies
have shown that NA-resistant viruses can rapidly acquire
mutations in NA after initiation of treatment,27,28 without
apparent loss of ﬁtness. Global circulation of such human
IAVs bearing antiviral resistancemutations has been observed
for different strains of inﬂuenza viruses in the past decade.29
Because the IAV genome consists of eight RNA segments,
coinfection of one host cell with two different IAVs can result
in progeny viruses containing gene segments derived from
both parental viruses. When the process of genetic reassort-
ment involves the gene segments encoding the HA and/or NA
genes, it is termed antigenic shift. Reassortment is an impor-
tant feature in IAV evolution18,30 and host switch.15
Viral Factors Contributing to Inﬂuenza
Pathogenesis
Considering viral factors speciﬁcally, the molecular basis of
virulence is also usually polygenic. Because IAV strains can
move between hosts to cause either self-limited spilloverajp.amjpathol.org - The American Journal of Pathology
Inﬂuenza Pathogenesisinfections or stably adapt to new hosts, viral pathogenesis
varies by host and must be considered when examining viral
virulence factors.
The processes bywhich IAV switch hosts, particularly those
changes associated with adaptation of avian IAV to mamma-
lian andultimatelyhumanhosts, havebeenextensively studied,
but are still only partially understood.15 Ultimately, inﬂuenza
viruses must be able to infect target cells, replicate, and be
transmitted efﬁciently to be adapted to a particular host.
However, inﬂuenza pathogenesis does not require trans-
missibility, and zoonotic infections of nonadapted, or partially
host-adapted, viruses can cause severe disease, such as
observed in human infections with avian H5N1 and H7N9
viruses.5,31 It is likely that viral adaptive mutations enhancing
replication, pathogenicity, and transmissibility in a particular
host are polygenic traits driven bymutational pressures that are
independent and possibly even competing.15,32,33
Virulence Factors Encoded by the Viral HA Gene
In seasonal inﬂuenza, rapid mutation of the antigenic re-
gions of the HA results in antigenic drift and the necessity to
continually reformulate the vaccine strains selected for in-
clusion. Emergence of antigenically drifted variants has
been associated with more severe annual epidemics (eg, the
1947 H1N1 epidemic) and more recent H3N2 variants in
1997 and 2003 to 2004.30,34,35 Lack of protective immunity
to pandemic IAV with antigenically novel HAs is also a
likely factor contributing to enhanced morbidity and mor-
tality in pandemics.36,37
Certain H5 or H7 strains of IAV can develop an inser-
tional polybasic mutation at the HA cleavage site in poultry
to become highly pathogenic avian inﬂuenza. These viruses
have enhanced pathogenicity because HA activation can use
intracellular furin-like proteases, allowing virus to replicate
systemically.1 These viruses typically cause severe illness
and high mortality in gallinaceous poultry, such as chickens
and turkeys, but may be nonpathogenic in ducks, further
supporting the species speciﬁcity of viral pathogenesis.38
Human zoonotic infections with highly pathogenic avian
inﬂuenza H5N1 viruses have been documented in 650 pa-
tients in 16 countries since 2003, with 386 deaths (59% case
fatality rate; World Health Organization, http://www.who.
int/inﬂuenza/human_animal_interface/EN_GIP_20140124
CumulativeNumberH5N1cases.pdf?uaZ1, last accessed
August 13, 2014).
The HA proteins encoded by the last four pandemic
viruses (1918 H1N1, 1957 H2N2, 1968 H3N2, and 2009
H1N1) cause enhanced disease in mice compared to seasonal
inﬂuenza H1N1 or H3N2 subtypes when expressed on a
chimeric IAV in which the other seven genes were derived
from a seasonal H1N1 human virus. These pandemic HA-
expressing viruses had an expanded cellular tropism to infect
alveolar epithelial cells and macrophages, and this was
correlated with an inability of these zoonotically derived HAs
to be neutralized by lung surfactant protein D in vitro.39 InThe American Journal of Pathology - ajp.amjpathol.orgaddition, viral constructs expressing the 1918 pandemic HA
on a seasonal H1N1 or H3N2 human virus40,41 showed
murine respiratory tract pathology similar to that induced by
the fully reconstructed 1918 virus, with a prominent inﬁltrate
of alveolar neutrophils and macrophages.39
Interestingly, in a recent study, a chimeric 1918 virus in
which its HA was replaced with a wild birdederived avian
H1 HA gene without any prior mammalian adaptation was
not attenuated and induced a pattern of disease and histo-
pathology indistinguishable from the fully reconstructed
1918 virus.42 This observation suggests that the HA viru-
lence factor associated with the 1918 pandemic might be
shared with avian inﬂuenza-derived H1 HAs.
Virulence Factors Encoded by the Viral Polymerase
Genes
The IAV polymerase genes have also been shown to contain
virulence factors in animal models. Chimeric IAVs encoding
the four RNP gene segments of the 1918 virus (PB2, PB1, PA,
and NP) in the context of the remaining genes from seasonal
inﬂuenza viruses showed enhanced pathogenicity in mice and
ferrets.43,44 Chimeric seasonal H1N1 viruses encoding the
PB1 gene of the 1918 virus enhanced viral replication in mice
and ferrets,41,44 whereas the PB1 gene from a seasonal
inﬂuenza virus attenuated the 1918 virus in mice.41,44
Experimental data suggest that the most efﬁcient inﬂuenza
transcriptional activity in vitrowas seen with an avian-derived
PB1 gene45; given that the 1918, 1957, and 1968 pandemic
viruses had avian inﬂuenza-like PB1 genes, there may be
ﬁtness advantages for human-adapted IAV strains to encode
an avian inﬂuenza-derived PB1 polymerase.46 The IAV PB1
segment also variably encodes a second protein in a second
reading frame, PB1-F2. The 1918 virus PB1-F2 was shown to
be a virulence factor related to a delay in innate immune re-
sponses.47,48 The 1918 PB1-F2 was also shown to enhance
the frequency and severity of secondary bacterial pneumonias
in mice.49 The PA segment encodes a second protein pro-
duced by ribosomal frame shifting. The 1918 PAX protein
modulated virulence in mice by decreasing pathogenicity.
The 1918 viral constructs with loss of PAX expression led to
changes in the kinetics of the host inﬂammatory response.24Host Factors Contributing to Inﬂuenza
Pathogenesis
Differences in the response of the host to inﬂuenza virus
infection can have profound effects on disease severity and
outcome. These can arise from preexisting medical conditions
and viral gene-dependent differential activation of host in-
ﬂammatory responses. Although most inﬂuenza virus in-
fections result in acute, self-limited infections with minimal
respiratory pathology, severe and fatal infections are associated
with hemorrhagic bronchitis, bronchiolitis, and alveolitis with
pulmonary edema and hemorrhage.6 As shown in Figure 21531
Figure 2 Representative pathological changes during fatal primary inﬂu-
enza and secondary bacterial infections in human autopsies from the 1918 (A,
C, and E) and 2009 (B, D, and F) pandemics. A: Immunohistochemical stained
section of lung from a 1918 pandemic inﬂuenza fatal case showing acute
inﬂuenza viral bronchiolitis with inﬁltration of neutrophils and other inﬂam-
matory cells in the lumen of a bronchiole (Br). Inﬂuenza viral antigen (reddish-
brown stain) is readily apparent in the apical cells of the bronchiolar respiratory
epithelium (inset), on a hematoxylin-stained background.50 B: Immunohisto-
chemical stained section of lung from a 2009 pandemic inﬂuenza fatal case
showing acute inﬂuenza viral bronchiolitis (Br). Inﬂuenza viral antigen (red-
dish-brown stain) is readily apparent in the apical cells of the bronchiolar
respiratory epithelium, on a hematoxylin-stained background.51 C:Hematoxylin
and eosin (H&E)estained section of lung from a 1918 pandemic inﬂuenza fatal
case showing diffuse alveolar damage with hyaline membranes lining alveoli.
The alveolar airspaces contain edema ﬂuid, strands of ﬁbrin, desquamated
epithelial cells, and inﬂammatory cells.50 D: H&E-stained section of lung from a
2009 pandemic inﬂuenza fatal case showing diffuse alveolar damage with hy-
aline membranes lining alveoli. The alveolar air spaces contain edema ﬂuid,
strands of ﬁbrin, desquamated epithelial cells, and inﬂammatory cells.51 E:
H&E-stained section of lung from a 1918 pandemic inﬂuenza fatal case showing
a massive inﬁltrate of neutrophils that ﬁlls the alveolar air spaces associated
with a secondary bacterial bronchopneumonia. Alveolar capillary congestion is
prominent.6 F: H&E-stained section of lung from a 2009 pandemic inﬂuenza
fatal case showing a massive inﬁltration of neutrophils in the airspaces of
alveoli associated with a secondary bacterial bronchopneumonia.51 A and C
were modiﬁed from Sheng et al (published by College of American Patholo-
gists),50 E from Taubenberger and Morens (published by Annual Reviews),6 and
B, D, and F from Gill et al (published by National Academy of Sciences of the
United States of America).51 All images used with permission of the publishers.
Original magniﬁcations: 40 (A and B); 100 (E and F); 200 (C and D).
Kash and Taubenberger(and the references therein), the pathological changes associated
with fatal primary viral and secondary bacterial pneumonias
were similar in both 1918 and 2009 pandemic autopsies.9,50,51
Role of Comorbidities and Genetic Predisposition
Essential epidemiological attributes of seasonal inﬂuenza and
pandemics are risk factors for severe complications and1532death. These include age, underlying chronic respiratory and
cardiovascular conditions, diabetes mellitus, pregnancy, and
immunosuppression. Both the young and old show increased
morbidity and mortality to both seasonal and pandemic
inﬂuenza viral infections, resulting in the typical U-shaped
age-speciﬁc mortality curves for pneumonia and inﬂuenza.4
Immunocompromised patients also have an increased risk
of enhanced disease after inﬂuenza infection and can shed
virus for manymonths, despite treatment with antiviral drugs,
such as NA inhibitors.52 Treatment of this patient population
with antiviral drugs, however, may also result in the rapid
accumulation of drug-resistance mutations. Immunocompro-
mised patients are signiﬁcantly more likely to have severe
disease/complications and radiological imaging abnormalities
while paradoxically demonstrating fewer clinical symptoms
and signs, such as dry cough, chills, sweats, myalgia, short-
ness of breath, chemosis, and neurological symptoms.52
Recently, a single-nucleotide polymorphism (rs12252-C)
in the interferon-inducible transmembrane 3 (IFITM3) gene
has been identiﬁed in hospitalized patients who were diag-
nosed with seasonal or 2009 pandemic H1N1 infections that
were associated with increased disease severity.53 Presence
of this single-nucleotide polymorphism was also shown to
be associated with increased cytokine expression and
plasma and death in patients diagnosed with H7N9 infec-
tion.54 Although the relationship of genetic predispositions
leading to enhanced disease is just beginning to emerge,55
numerous studies have shown a clear correlation between
inﬂuenza viral pathogenesis and robust immune and in-
ﬂammatory responses.
Role of Inﬂammatory Responses in Disease Severity
Numerous studies have shown an association between
fulminant inﬂuenza virus infections with robust activation of
host inﬂammatory responses.56e58 These responses include
high levels of expression of cytokines, chemokines, and
acute phase response reactants. These aberrant inﬂammatory
responses lead to activation of immune cells and cell death
responses and result in immunopathologies that contribute to
disease severity. Signiﬁcantly, transcriptomic analysis of a
1918 pandemic autopsy sample59 showed a marked concor-
dance with studies in mice57 and cynomolgus macaques,58
revealing that signiﬁcant activation of inﬂammatory and
cell death responses, as seen in experimental animals, was
also observed in a clinical specimen. The killing of infected
cells by immune cells, such as macrophages, natural killer
cells, cytotoxic T cells, and neutrophils, is a key component
of the inﬂammatory response.
Immune cell-mediated killing occurs through a variety of
mechanisms, including secretion of perforin, proteases,
activation of cell death via death receptor ligands like tumor
necrosis factor and FasL, and the production of reactive ox-
ygen species (ROS). The in situ generation of ROS by neu-
trophils and macrophages, catalyzed by the NADPH-oxidase
system, produces hydrogen peroxide and other ROS.60e63ajp.amjpathol.org - The American Journal of Pathology
Figure 3 Relationship between pathological changes and host responses during severe primary inﬂuenza and secondary bacterial infections in human autopsies and
experimental animal infections. Necrotizing tracheitis (1) in a 2009 pandemic H1N1 fatality.51 Inset shows the relative expression of inﬂammatory and type I interferon
(IFN) gene expression responses in fatal 1918 inﬂuenza infection compared to seasonal virus in cynomolgusmacaques.58 Severe necrotizing bronchitis/bronchiolitis (2) in
a 1918 inﬂuenza autopsy sample showing intense viral antigen staining in the ciliated and goblet cells of the respiratory epithelium, but not in basal cells.50 Inset shows
the relative expression of inﬂammatory response and cell death genes in lungs of mice infected with 1918 compared to seasonal H1N1.58 Secondary bacterial pneumonias
(3) with massive inﬁltration of neutrophils into alveolar airspaces in a 1918 pandemic inﬂuenza13 fatal case (right panel). Left panel: Gram stain showing presence of
Streptococcus pneumoniae bacteria (arrows) on remaining basal epithelial cells (nuclei labeled BC) and a macrophage (M) in mouse lung after coinfection of 2009
pandemic H1N1 and S. pneumoniae.72 Inset shows loss of lung repair and regeneration gene expression responses in mice infected with 2009 pandemic H1N1 with a
secondary S. pneumoniae infection compared to primary 2009 pandemic H1N1 infection.66 Development of diffuse alveolar damage (DAD) (4) with alveolar hyaline
membrane formation, varying degrees of acute intra-alveolar edema, acute hemorrhage, interstitial and airspace inﬂammatory inﬁltrates, and small-vessel thromboses in
1918 pandemic inﬂuenza (top panel)6,9,51 and 2009 pandemic inﬂuenza (bottom panel)51 autopsies, along with pronounced alveolar epithelial immunostaining for
reactive oxygen species (ROS) damage in mouse tissue infected with 1918 inﬂuenza virus.66 Inset shows relative expression of inﬂammatory and ROS response genes in
lungs of mice infected with 1918 compared to seasonal H1N1.66 Photomicrograph in 1 was modiﬁed from Gill et al (published by National Academy of Sciences of the
United States of America)51; in 2 from Sheng et al (published by College of American Pathologists)50; in 3 fromMorens et al (published by Oxford University Press)13 (right
panel) and Kash et al (published by American Society for Microbiology)72 (left panel); and in 4 from Taubenberger and Morens (published by Annual Reviews)6 (top
panel), Kash et al (published by Elsevier B.V.)66 (middle panel), and Gill et al (published by National Academy of Sciences of the United States of America)51 (bottom
panel). All images used with permission of the publishers.
Inﬂuenza PathogenesisROS cause oxidation of cellular proteins, lipids, and DNA
and result in cellular dysfunction or death.64,65 In animal
models, highly pathogenic inﬂuenza viruses, such as 1918
virus, cause signiﬁcant activation of antiviral, proin-
ﬂammatory, ROS, and cell death responses during infection.The American Journal of Pathology - ajp.amjpathol.orgIn the case of 1918 virus, these exaggerated immune re-
sponses lead to severe necrotizing bronchitis, bronchiolitis,
neutrophil-predominant alveolitis, acute edema, and pulmo-
nary hemorrhage.57 Recently, we reported that treatment of
mice infected with a lethal dose of the 1918 inﬂuenza virus1533
Kash and Taubenbergerwith a catalytic ROS scavenging organometallic drug with
superoxide dismutase and catalase mimetic activity increased
survival.66 In this study, drug treatment resulted in decreased
severity of lung pathology and greatly reduced ROS damage,
but did not affect viral replication.66Bacterial Factors Contributing to Inﬂuenza
Pathogenesis
Primary inﬂuenza viral infections have been associated with
secondary bacterial infections since the late 19th century.13
Although the use of antibiotics has had an impact on second-
ary bacterial infections, bacterial pneumonia after a primary
inﬂuenza infection remains a signiﬁcant threat to public health.
During the 1918 inﬂuenza pandemic, most of the 50 million
worldwide deaths were associatedwith concurrent or secondary
bacterial infections, primarily with Gram-positive bacteria.13
Secondary bacterial infections also increased morbidity and
mortality during the 1957 H2N2 and 1968 H3N2 pandemics.
Even in the era of widespread antibiotic use, bacterial infections
were identiﬁed in up to 34% of 2009 H1N1 pandemic inﬂuenza
cases managed in intensive care units and up to 55% of fatal
cases.12,51 The bacteria most frequently associated with sec-
ondary infections after inﬂuenza are the pneumopathogens
Staphylococcus aureus, including methicillin-resistant strains,
Streptococcus pneumoniae, and S. pyogenes.12,13 Thus, the
increased susceptibility to the complication of secondary bac-
terial infections should be considered as an intrinsic virulence
property of inﬂuenza viruses.
Numerous mechanisms have been proposed and experi-
mentally shown to participate in the development of secondary
bacterial pneumonias. These include increased colonization of
the upper respiratory tract due to loss of physical barriers that
inhibit the introduction of bacteria into the lung, such as ne-
crosis of airway epithelial cells that can result in loss of
mucociliary clearance, which facilitates colonization of the
lungs with bacteria present in the oronasopharynx.67 The
damaged surfaces of the airways with associated ﬁbrin depo-
sition, tissue repair, regenerative processes, and the sialidase
activity of the viral NA can result in the exposure of bacterial
attachment sites.68,69
Studies in mice have shown that primary inﬂuenza viral
infection can inhibit the Th17 pathway and suppress macro-
phage function, including inhibition of NADPH-oxidasee
dependent phagocytic bacterial clearance, leading to more
severe secondary bacterial pneumonias.70,71 Our group has
shown that another pathogenic mechanism of bacterial sec-
ondary pneumonia is the loss of lung repair responses and loss
of basal epithelial cells required for reestablishment of the
airway epithelium, including type I and II alveolar epithelial
cells. Loss of basal cells was associated with bacterial
attachment and apoptosis, suggesting a direct role of the
bacteria in death of this essential cell population.72
Once a secondary bacterial infection is established, the
blockage and loss of small airway function from cell debris1534and proteinaceous edema ﬂuid and the development of
exudative transmural pleuritis can severely compromise the
respiratory system.67,73 Increased lung damage and loss of
repair processes would also lead to loss of tissue integrity
and contribute to the development of bacteremia. Thus, the
risk of bacterial pneumonia may relate to increasing inﬂu-
enza viral pathogenicity, resulting in primary viral epithelial
cell damage, bacterial invasion, and decreased lung repair
due to loss of respiratory epithelial progenitor basal cells.72Conclusions
Inﬂuenza viruses pose signiﬁcant public health threats
whether examining the impact of seasonal inﬂuenza epi-
demics, zoonotic outbreaks, or the unpredictable emer-
gence of novel pandemic viruses. Although most inﬂuenza
infections are acute and self-limited, a set of multifactorial
processes involving interrelated host, viral, and bacterial
factors is involved in disease progression, leading to the
development of pneumonia and death in a subset of patients
(Figure 3).
Inﬂuenza virus infections can involve all levels of the res-
piratory tree, and infection of the respiratory epithelium cor-
responds to the clinical signs and symptoms of tracheitis and
bronchitis.6 Pathologically, inﬂuenza infection may be asso-
ciated with severe, necrotizing tracheitis and bronchitis/bron-
chiolitis (Figure 3), where highly virulent infections are
associated with lack of activation of many antiviral responses,
such as expression of type I interferons, andmarked expression
of proinﬂammatory cytokines and chemokines (Figure 3).
Secondary or coincident bacterial pneumonias frequently
occur and complicate the pathological picture. In such
cases, a massive inﬁltration of neutrophils into alveolar
airspaces is usually observed, resulting in signiﬁcant tissue
damage that is enhanced by the concomitant loss of lung
repair and consequently results in severe respiratory
compromise (Figure 3).
Autopsy studies in humans and necropsy studies in
experimental animals have helped elucidate the character-
istic changes of severe inﬂuenza viral pneumonia, including
the development of diffuse alveolar damage with alveolar
hyaline membrane formation, varying degrees of acute intra-
alveolar edema and/or acute hemorrhage, interstitial and
airspace inﬂammatory inﬁltrates, and small-vessel throm-
boses.6 These changes correspond clinically to acute respi-
ratory distress syndrome and are associated with increased
ROS damage and cell stress responses (Figure 3). In later
stages, organizing diffuse alveolar damage and changes
associated with repair (eg, ﬁbrosis, epithelial regeneration,
and squamous metaplasia) are commonly observed.9
Although the multifactorial processes cannot, in general, be
separated in a patient with severe inﬂuenza, experimental ani-
mal models have greatly contributed to our understanding of
how different factors interact to enhance inﬂuenza disease. A
better understanding of these processes is critically importantajp.amjpathol.org - The American Journal of Pathology
Inﬂuenza Pathogenesisfor our ability to develop new therapeutic modalities to improve
outcomes in high-risk patients and patients with severe disease.References
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